188 related articles for article (PubMed ID: 12149286)
21. Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
Kurtzhalts K; Gee ME; Feuz L; Krajewski KC
Am J Health Syst Pharm; 2016 Oct; 73(19):1508-11. PubMed ID: 27646812
[TBL] [Abstract][Full Text] [Related]
22. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
Droller MJ
J Urol; 2001 Feb; 165(2):701-2. PubMed ID: 11233047
[No Abstract] [Full Text] [Related]
24. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
[TBL] [Abstract][Full Text] [Related]
25. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
[TBL] [Abstract][Full Text] [Related]
26. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Perdonà S; Di Lorenzo G; Cantiello F; Damiano R; De Sio M; Masala D; Bruni G; Gallo L; Federico P; Quattrone C; Pizzuti M; Autorino R
Anticancer Drugs; 2010 Jan; 21(1):101-6. PubMed ID: 19858710
[TBL] [Abstract][Full Text] [Related]
27. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
[TBL] [Abstract][Full Text] [Related]
28. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
29. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
30. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Gontero P; Marini L; Frea B
BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
[No Abstract] [Full Text] [Related]
31. [Intravesical therapy of non-muscle invasive bladder tumors].
Vom Dorp F; Tschirdewahn S; Lümmen G
Urologe A; 2012 Feb; 51(2):257-64. PubMed ID: 22331075
[TBL] [Abstract][Full Text] [Related]
32. [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Lebret T
Prog Urol; 2008 May; 18 Suppl 5():S111-4. PubMed ID: 18585632
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
[TBL] [Abstract][Full Text] [Related]
34. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
35. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
36. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results.
Bazarbashi S; Raja MA; El Sayed A; Ezzat A; Ibrahim E; Kattan S; Kardar A; Peracha A; Lindstedt E; Hanash K
J Surg Oncol; 2000 Jul; 74(3):181-4. PubMed ID: 10951412
[TBL] [Abstract][Full Text] [Related]
37. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
38. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
39. Is intravesical chemotherapy for superficial bladder cancer still justified?
Okeke AA; Probert JL; Gillatt DA; Schwaibold H
BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
[No Abstract] [Full Text] [Related]
40. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
